Strengthens capabilities in peptide therapeutics and CDMO services
Granules India announced the successful closing of the acquisition of Senn Chemicals, a Swiss-based Contract Development and Manufacturing Organization (CDMO) specialising in peptide development and manufacturing.
The acquisition follows the signing of a definitive share purchase agreement in February 2025, under which Granules, through its wholly owned Indian subsidiary, Granules Peptides acquired 100 per cent of the equity of Senn Chemicals from the founding Senn family.
The Senn Chemicals brand and its operations in Dielsdorf, Switzerland, will operate under Granules’ ownership, with a commitment to maintaining the company’s scientific excellence and customer focus.
Dr Krishna Prasad Chigurupati, CMD, Granules India, said, “The acquisition of Senn Chemicals AG marks a pivotal step in Granules’ strategic evolution into a science- and innovation-led organisation. By entering the rapidly growing peptide therapeutics segment and building on Senn’s specialised CDMO capabilities, we are well-positioned to deliver high-quality, next-generation treatments. Senn’s specialised expertise in peptide development and its strong customer relationships complement Granules’ manufacturing strength and global reach. Together, we aim to drive meaningful impact in the complex therapeutics space.”
The acquisition will enable Granules to accelerate the development and manufacturing of GLP-1 receptor agonists and other peptide-based APIs, addressing the growing demand in anti-diabetic, anti-obesity, and other next-generation therapeutic areas. Granules and Senn have already initiated joint development activities in this space, with a broader peptide API pipeline planned.
The transaction also marks Granules’ foray into the CDMO space, with Senn’s established CDMO business providing a strong platform for growth. The acquisition enhances Granules’ global footprint and provides access to a regulated market client base and highly skilled scientific talent in Europe.
